Pulling SEC filings + quote and writing the call…

Immunome Inc.
Next earnings Aug 4, 2026 · consensus $-0.54 EPS, $185K rev
Last earnings -1.3% on 2026-05-12
Conservative balance sheet (liabilities/equity 0.08x); but revenue fell -23.2% YoY.
Immunome Inc. shows $6.94M in FY2025 revenue (-23.2% YoY), a -3060.0% net margin, and -33.5% ROE.
Sources: SEC EDGAR (CIK 0001472012, latest 10-Q filed 2026-05-12) · EODHD · as of 6/25/2026, 5:38:29 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | $14.0M | $9.04M | $6.94M |
| Gross profit | — | — | — | — | — |
| Operating income | -$25.2M | -$36.9M | -$110M | -$306M | -$224M |
| Net income | -$24.7M | -$36.9M | -$107M | -$293M | -$212M |
| Diluted EPS | -$2.14 | -$3.09 | -$5.38 | -$5.00 | -$2.43 |
| Net margin | — | — | -761.9% | -3240.4% | -3060.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1079 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 3 open-market buys · 3 sales
| 2026-06-15 | Rosett Max Chief Financial Officer | Exercise | 60.0K @ $1.05 | $63.0K |
| 2026-06-15 | Rosett Max Chief Financial Officer | Sell | 60.0K @ $18.23 | $1.09M |
| 2026-06-05 | BIENAIME JEAN JACQUES Director | Sell | 500.00 @ $19.44 | $9.72K |
| 2026-06-05 | BIENAIME JEAN JACQUES Director | Sell | 10.0K @ $19.41 | $194K |
| 2026-06-05 | BIENAIME JEAN JACQUES Director | Buy | 6.00K @ $19.48 | $117K |
| 2026-06-05 | BIENAIME JEAN JACQUES Director | Buy | 3.50K @ $19.46 | $68.1K |
| 2026-06-05 | BIENAIME JEAN JACQUES Director | Buy | 1.00K @ $19.27 | $19.3K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.